Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice

Nature Communications

Volumn 8, Issue 1, 2017, Pages

  He, Wenqian ^a   Chen, Chi Jene ^a   Mullarkey, Caitlin E ^a   Hamilton, Jennifer R ^a   Wong, Christine K ^a   Leon, Paul E ^a   Uccellini, Melissa B ^a   Chromikova, Veronika ^a   Henry, Carole ^b   Hoffman, Kevin W ^a   Lim, Jean K ^a   Wilson, Patrick C ^b   Miller, Matthew S ^c   Krammer, Florian ^a   Palese, Peter ^a   Tan, Gene S ^a,d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d J CRAIG VENTER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD161 ANTIGEN; CHEMOKINE; CLODRONIC ACID; CYTOKINE; EOTAXIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; INFLUENZA VACCINE; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2B9; MONOCLONAL ANTIBODY 6F12; MONOCLONAL ANTIBODY 9H10; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTRALIZING ANTIBODY; RANTES; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; FC RECEPTOR; HEMAGGLUTININ;

ANTIBODY; CELLS AND CELL COMPONENTS; IMMUNE SYSTEM; IMMUNIZATION; INFLUENZA; RODENT; VIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; HEK293 CELL LINE; HUMAN; HUMAN CELL; IMMUNE SYSTEM; INFLUENZA A; INFLUENZA A VIRUS; INFLUENZA A VIRUS (H3N2); INFLUENZA VACCINATION; INNATE IMMUNITY; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; MOUSE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; VIRUS REPLICATION; A-549 CELL LINE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DOG; IMMUNOLOGY; INFLUENZA; KNOCKOUT MOUSE; MACROPHAGE ACTIVATION; MDCK CELL LINE; METABOLISM; ORTHOMYXOVIRUS INFECTION; PHYSIOLOGY;

CERCOPITHECINE HERPESVIRUS 1; INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE;

A549 CELLS; ANIMALS; ANTIBODIES, NEUTRALIZING; DOGS; FEMALE; HEK293 CELLS; HEMAGGLUTININS; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; KILLER CELLS, NATURAL; MACROPHAGE ACTIVATION; MACROPHAGES, ALVEOLAR; MADIN DARBY CANINE KIDNEY CELLS; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUTROPHILS; ORTHOMYXOVIRIDAE INFECTIONS; PHAGOCYTOSIS; RECEPTORS, IGG;

EID: 85031008840     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-017-00928-3     Document Type: Article

References (55)

1. World Health Organization, Geneva, S. Fact Sheet 211: Influenza http://www. who.int/mediacentre/factsheets/fs211/en/ (2014).
2. Shaw, M. L. & Palese, P. Fields Virology. Orthomyxoviridae: The Viruses and Their Replication (Lippincott Williams & Wilkins, 2013).
3. Bouvier, N. M. & Palese, P. The biology of influenza viruses. Vaccine 26, D49-D53 (2008).
4. Sandbulte, M. R. et al. Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses. Proc. Natl Acad. Sci. USA 108, 20748-20753 (2011).
5. Ekiert, D. C. et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489, 526-532 (2012).
6. Dean, A. S. et al. Incompletely matched influenza vaccine still provides protection in frail elderly. Vaccine 28, 864-867 (2010).
7. Co, M. D. T., Cruz, J., Takeda, A., Ennis, F. A. & Terajima, M. Comparison of complement dependent lytic, hemagglutination inhibition and microneutralization antibody responses in influenza vaccinated individuals. Hum. Vaccin. Immunother. 8, 1218-1222 (2012).
8. Hancock, K. et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N. Engl. J. Med. 361, 1945-1952 (2009).
9. Dilillo, D. J., Palese, P., Wilson, P. C. & Ravetch, J. V. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J. Clin. Invest. 126, 605-610 (2016).
10. Dunand, C. J. H. et al. Both neutralizing and non-neutralizing human H7N9 influenza vaccine-induced monoclonal antibodies confer protection. Cell Host Microbe 19, 800-813 (2016).
11. Tan, G. S. et al. Broadly-reactive neutralizing and non- neutralizing antibodies directed against the H7 influenza virus hemagglutinin reveal divergent mechanisms of protection. PLoS Pathog. 12,1-21 (2016).
12. El Bakkouri, K. et al. Universal vaccine based on ectodomain of matrix protein 2of influenza A: Fc receptors and alveolar macrophages mediate protection. J. Immunol. 186, 1022-1031 (2011).
13. LaMere, M. et al. Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J. Immunol. 186, 4331-4339 (2012).
14. Dilillo, D. J., Tan, G. S., Palese, P. & Ravetch, J. V. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcyR interactions for protection against influenza virus in vivo. Nat. Med. 20, 143-151 (2014).
15. Tan, G. S. et al. Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. J. Virol. 88, 13580-13592 (2014).
16. Castell, J. V. et al. Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the ra. t. Eur. J. Biochem. 361, 357-361 (1988).
17. Klapproth, J., Geiger, T. & Heinrich, P. C. Fate and biological action of human recombinant interleukin lp in the rat in vivo. Eur. J. Immunol. 19, 1485-1490 (1989).
18. Beutler, B., Milsark, I. & Cerami, A. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J. Immunol. 135,3972-3977 (1985).
19. Wrammert, J. et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208, 181-193 (2011).
20. Tumpey, T. M. et al. Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. J. Virol. 79, 14933-14944 (2005).
21. Kim, H. M. et al. Alveolar macrophages are indispensable for controlling influenza viruses in lungs of pigs. J. Virol. 82, 4265-4274 (2008).
22. Man, H. et al. The severe pathogenicity of alveolar macrophage-depleted ferrets infected with 2009 pandemic H1N1 influenza virus. Virology 444, 394-403 (2013).
23. Fels, A. O. & Cohn, Z. A. The alveolar macrophage. J. Appl. Physiol. 60, 353-369 (1986).
24. Ghoneim, H. E., Thomas, P. G. & Jonathan, A. Depletion of alveolar macrophages during influenza infection facilitates bacterial superinfections. J. Immunol. 191, 1250-1259 (2013).
25. Paine, R. et al. Impaired functional activity of alveolar macrophages from GM-CSF-deficient mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 281, L1210-L1218 (2001).
26. Schultz-Cherry, S. Role ofNK Cells in Influenza Infection (Springer, 2015).
27. Koo, G. C. & Peppard, J. R. Establishment ofmonoclonal anti-Nk-1.1 antibody. Hybridoma 3, 301-303 (1984).
28. Carlyle, J. R. et al. Molecular and genetic basis for strain-dependent NK1.1 alloreactivity of mouse NK cells. J. Immunol. 176, 7511-7524 (2006).
29. Mesci, A., Ljutic, B., Makrigiannis, A. P. & Carlyle, J. R. NKR-P1 biology: from prototype to missing self. Immunol. Res. 35,13-26 (2006).
30. Galani, I. E. & Andreakos, E. Neutrophils in viral infections: current concepts and caveats. J. Leukoc. Biol. 98, 557-564 (2015).
31. Daley, J. M., Thomay, A. A., Connolly, M. D., Reichner, J. S. & Albina, J. E. Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J. Leukoc. Biol. 83,64-70 (2008).
32. Tan, G. S. et al. A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J. Virol. 86, 6179-6188 (2012).
33. Baudino, L. et al. Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions. J. Immunol. 181, 6664-6669 (2008).
34. Murphy, K. Janeway's Immunobiology (Garland Science, 2012).
35. Jonsson, F. & Daeron, M. Mast cells and company. Front. Immunol. 3,1-18 (2012).
36. Krammer, F., Palese, P. & Steel, J. Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin. Curr. Top. Microbiol. Immunol. 386, 301-321 (2015).
37. Impagliazzo, A., Milder, F., Kuipers, H., Wagner, M. V. & Zhu, X. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349, 1301-1306 (2015).
38. Leon, P. E. et al. Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact. Proc. Natl Acad. Sci. USA 113, E5944-E5951 (2016).
39. He, W. et al. Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus. Proc. Natl Acad. Sci. USA 113, 11931-11936 (2016).
40. Jegaskanda, S., Reading, P. C. & Stephen, J. Influenza-specific antibody-dependent cellular cytotoxicity: toward a universal influenza vaccine. J. Immunol. 193, 469-475 (2014).
41. Zhong, W. et al. Antibody-dependent cell-mediated cytotoxicity to hemagglutinin of influenza a viruses after influenza vaccination in humans. Open Forum Infect. Dis. 3, ofw102 (2016).
42. Jegaskanda, S. et al. Age-associated cross-reactive antibody- dependent cellular cytotoxicity toward 2009 pandemic influenza a virus subtype H1N1. J. Infect. Dis. 208, 1051-1061 (2013).
43. Jegaskanda, S. et al. Generation and protective ability of influenza virus-specific antibody-dependent cellular cytotoxicity in humans elicited by vaccination, natural infection, and experimental challenge. J. Infect. Dis. 214, 945-952 (2016).
44. Divangahi, M., King, I. L. & Pernet, E. Alveolar macrophages and type I IFN in airway homeostasis and immunity. Trends Immunol. 36, 307-314 (2015).
45. Hussell, T. & Bell, T. J. Alveolar macrophages: plasticity in a tissue-specific context. Nat. Rev. Immunol. 14,81-93 (2014).
46. Overdijk, M. B. et al. Crosstalk between Human IgG Isotypes and murine effector cells. J. Immunol. 189, 3430-3438 (2012).
47. Stewart, R. et al. The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer. J. Immunother. Cancer 2, 29 (2014).
48. Mullarkey, C. E. et al. Broadly neutralizing hemagglutinin stalk-specific antibodies induce potent phagocytosis of immune complexes by neutrophils in an fc-dependent manner. MBio. 7, e01624-16 (2016).
49. Jegaskanda, S. et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J. Immunol. 190, 1837-1848 (2013).
50. Nimmerjahn, F. & Ravetch, J. V. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8,34-47 (2008).
51. Bruhns, P. & Jonsson, F. Mouse and human FcR effector functions. Immunol. Rev. 268,25-51 (2015).
52. He, W. et al. Broadly-neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones. J. Virol. 89, 3610-3618 (2015).
53. He, W., Mullarkey, C. E. & Miller, M. S. Measuring the neutralization potency of influenza A virus hemagglutinin stalk/stem-binding antibodies in polyclonal preparations by microneutralization assay. Methods 90,95-100 (2015).
54. Krammer, F. et al. A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates. PLoS ONE 7, e43603 (2012).
55. Ackerman, M. E. et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J. Immunol. Methods 366,8-19 (2011).